Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Venous Occlusion clinical trials
2 of 5 indexed Venous Occlusion trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Venous Occlusion: 5 US clinical trials tracked, 2 recruiting.
Venous Occlusion is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. The most active sponsor is Merit Medical Systems, running 3 of these trials.
Enrollment posture brief
Registry condition venous-occlusion
OPEN 2 | RECR 40% | LATE 0 | EARLY 0 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Venous Occlusion lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Venous Occlusion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Venous Occlusion is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Venous Occlusion research.
Merit Medical Systems accounts for 3 of 5 trials (60%). 2 distinct sponsors appear on at least one study for this condition label.
-
Typical Venous Occlusion enrolment sits around 165 participants.
Median target enrolment is 165 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Venous Occlusion research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
WRAP North America
Merit Medical Systems
NCT06807099
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
W.L.Gore & Associates
NCT05489588
The Merit WRAPSODY AV Access Efficacy Study (WAVE)
Merit Medical Systems
NCT04540302
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
W.L.Gore & Associates
NCT05409976
Evaluation of the Surfacer System Approach to Central Venous Access
Merit Medical Systems
NCT03209050
Phase Distribution
Phase data not available
Top Sponsors
Named interventions
Most-linked intervention names on Venous Occlusion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Venous Occlusion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Venous Occlusion page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Venous Occlusion trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Merit Medical Systems sponsors the most Venous Occlusion trials on record, review their full trial history before evaluating a specific study. See Merit Medical Systems's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Venous Occlusion condition card totals 5 registered trials; most-linked intervention GORE® VIAFORT Vascular Stent; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.